Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Opus Genetics, Inc. (IRD)

Opus Genetics CSDO Ashwath Jayagopal transitions to six-month consulting role

Neutral Impact 3 of 5 leadership Written later

Opus Genetics said Chief Scientific and Development Officer Ashwath Jayagopal will step out of that role effective October 19, 2026, and move into a six-month consulting arrangement to provide transition services at the company's request. The change is an executive departure at a senior scientific and development post, and the filing gives no successor name.

Key points

  • Ashwath Jayagopal's role as Chief Scientific and Development Officer ends with a separation date of October 19, 2026.
  • He will provide transition services under a six-month consulting arrangement, paid at $250 per hour.
  • His outstanding vested options as of the separation date stay exercisable during the consulting term.
  • The full letter agreement will be filed as an exhibit to the Form 10-K for the fiscal year ended December 31, 2026.

The filing

CompanyOpus Genetics, Inc. (IRD)
Form8-K, current report
Filed with the SECOct 21, 2026, 4:05 PM ET
Accession number0001140361-26-040377

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.